Welcome to our dedicated page for Arcus Bioscience news (Ticker: RCUS), a resource for investors and traders seeking the latest updates and insights on Arcus Bioscience stock.
Arcus Biosciences, Inc. (NYSE: RCUS) generates frequent news as a clinical-stage, global biopharmaceutical company advancing investigational therapies for cancer, inflammatory diseases and autoimmune diseases. News about Arcus often centers on clinical trial updates for its lead programs, collaboration developments and corporate financing activities that support its pipeline.
Key oncology news items include data readouts and study milestones for casdatifan, a small-molecule HIF‑2α inhibitor being developed for clear cell renal cell carcinoma (ccRCC). Investors can follow announcements from the ARC‑20 Phase 1/1b study in late-line and early-line ccRCC, the global Phase 3 PEAK‑1 trial in immunotherapy-experienced metastatic ccRCC, and the eVOLVE‑RCC02 Phase 1b/3 study that combines casdatifan with volrustomig in first-line metastatic ccRCC. Updates often highlight progression-free survival, response rates, safety findings and the design of new cohorts or registrational strategies.
Arcus news also covers its broader oncology portfolio, including quemliclustat, a CD73 inhibitor in the PRISM‑1 Phase 3 trial for first-line metastatic pancreatic ductal adenocarcinoma, and the domvanalimab plus zimberelimab combinations in gastrointestinal and lung cancers. Coverage has included positive survival and response data from the Phase 2 EDGE‑Gastric study, as well as the later decision to discontinue the Phase 3 STAR‑221 and EDGE‑Gastric studies after an interim analysis showed no overall survival benefit over standard therapy.
On the inflammation and immunology side, Arcus issues updates on its emerging small-molecule programs targeting MRGPRX2, TNF, CCR6 and CD40L, and an anti‑CD89 antibody program. News may describe preclinical progress, selection of development candidates and plans to enter the clinic in indications such as atopic dermatitis, chronic spontaneous urticaria, rheumatoid arthritis, psoriasis, inflammatory bowel disease, multiple sclerosis and systemic lupus erythematosus.
Corporate and financial news for RCUS includes public equity offerings, amendments to loan facilities, participation in major healthcare and investor conferences, and guidance on cash runway. Readers can use this news page to follow how clinical data, partnership decisions with Gilead Sciences and Taiho Pharmaceutical, and capital-raising activities shape Arcus’s development priorities over time.
Arcus Biosciences (NYSE:RCUS) presented new data for casdatifan, their HIF-2a inhibitor for metastatic kidney cancer, showing promising results across three monotherapy cohorts. The 50mg twice-daily cohort achieved a 9.7-month median progression-free survival, while other cohorts had not yet reached their median.
Key findings include a 33% confirmed response rate in the 100mg cohort using tablet formulation, which is the expected go-forward dose for pivotal studies. Across all cohorts, 81-87% of patients experienced disease control with either partial response or stable disease. The study involved heavily pretreated patients, with 52-59% having received at least three prior lines of therapy.
Casdatifan demonstrated an acceptable safety profile, with low discontinuation rates. The company plans to advance the drug through multiple development programs, including the Phase 3 PEAK-1 study in combination with cabozantinib.
Arcus Biosciences (NYSE:RCUS) has announced new employment inducement grants for its recently appointed Chief Medical Officer, Dr. Richard Markus, and two new employees. Dr. Markus received an option to purchase 305,328 shares of common stock at $12.45 per share and restricted stock units for 75,193 shares. Additionally, two new employees were granted options to purchase 9,150 shares at $12.45 per share and restricted stock units for 4,600 shares. These equity awards were granted under the Company's 2020 Inducement Plan, approved under NYSE Listed Company Manual Rule 303A.08's inducement exception.
Arcus Biosciences (NYSE:RCUS) announced upcoming presentation of new data from their ARC-20 study at the 2025 ASCO GU Symposium. The presentation will showcase safety and efficacy data for casdatifan, their HIF-2a inhibitor, in treating clear cell renal cell carcinoma (ccRCC).
The presentation will include initial data from the 100mg once-daily tablet cohort, which is their selected dose for Phase 3 studies, along with updated data from the 50mg twice-daily and 50mg once-daily expansion cohorts. Dr. Toni Choueiri from Dana-Farber Cancer Institute will present the findings on February 15, 2025.
Arcus is advancing casdatifan's development program, including the planned initiation of their Phase 3 study (PEAK-1) in the first half of 2025, a clinical collaboration with AstraZeneca to evaluate casdatifan in combination with volrustomig, and new cohorts to evaluate the treatment in first-line settings.
Arcus Biosciences (NYSE:RCUS) has announced new employment inducement grants approved by its Compensation Committee. The grants include stock options for 31,800 shares at an exercise price of $13.33 per share and restricted stock units for 16,000 shares of common stock. These equity awards were granted to four new employees under the company's 2020 Inducement Plan, which was established under NYSE Listed Company Manual Rule 303A.08's inducement exception. The exercise price reflects the closing price of RCUS stock on January 23, 2024.
Arcus Biosciences (NYSE:RCUS) has appointed Richard Markus, M.D., Ph.D. as Chief Medical Officer, effective January 31, 2025, replacing Dimitry Nuyten, M.D., Ph.D. Dr. Markus will oversee the company's clinical development organization and portfolio, which includes seven clinical-stage programs with multiple Phase 3 studies.
The company plans to initiate PEAK-1, its fifth registrational Phase 3 study, in the first half of 2025, evaluating casdatifan plus cabozantinib in clear-cell renal cell carcinoma patients. Dr. Markus brings extensive experience from his 13-year tenure at Amgen, where he served as vice president of global development and oversaw multiple product approvals. Most recently, he founded Dantari, a clinical-stage oncology-focused antibody-drug conjugate company.
Arcus Biosciences (NYSE:RCUS) has granted equity awards to four new employees through its 2020 Inducement Plan. The grants include options to purchase 66,900 shares of common stock at an exercise price of $15.96 per share, which matched the closing price on December 23, 2024. Additionally, the employees received restricted stock units to acquire 33,450 shares of common stock. These awards were approved by the Compensation Committee under the NYSE Listed Company Manual Rule 303A.08 inducement exception.
Arcus Biosciences (NYSE:RCUS), a clinical-stage biopharmaceutical company specializing in cancer therapeutics, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco. CEO Terry Rosen, Ph.D., will deliver a presentation on Tuesday, January 14th, 2025, at 3:45pm PT. The presentation will be accessible via live webcast through the 'Investors & Media' section of the company's website, with a replay option available after the event.
Arcus Biosciences (NYSE:RCUS), a clinical-stage biopharmaceutical company focused on cancer therapies, has granted equity awards to two new employees. The Compensation Committee approved stock options to purchase 7,400 shares at $17.47 per share (the closing price on December 9, 2024) and restricted stock units for 3,700 shares. These equity awards were granted under the Company's 2020 Inducement Plan, which was established under NYSE Listed Company Manual Rule 303A.08's 'inducement exception'.
Arcus Biosciences (NYSE:RCUS) has announced new employment inducement grants approved by its Compensation Committee. The grants include options to purchase 10,000 shares of common stock at an exercise price of $14.56 per share, and restricted stock units to acquire 5,000 shares of common stock. These equity awards were granted to three new employees under the Company's 2020 Inducement Plan, which was established under NYSE Listed Company Manual Rule 303A.08's inducement exception.
Arcus Biosciences (NYSE:RCUS), a clinical-stage biopharmaceutical company developing cancer therapies, has announced its participation in two major investor conferences in December 2024. The company will attend the Evercore 7th Annual HealthCONx Conference in Coral Gables, FL on December 3rd, featuring a fireside chat at 7:55 a.m. ET and one-on-one meetings. Additionally, Arcus will participate in the Citi 2024 Global Healthcare Conference in Miami, FL on December 4th for one-on-one meetings only. Live webcasts and replays will be available on the company's website.